103 results
8-K
EX-10.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Departure of Directors or Certain Officers
4:16pm
% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective
424B5
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Prospectus supplement for primary offering
5:23pm
the debenture trustee or holders of not less than a majority in aggregate principal amount of the outstanding debt securities of the applicable series … at the time outstanding occurs and is continuing, then the trustee or the holders of not less than a majority in principal amount of the outstanding
424B5
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Prospectus supplement for primary offering
4:37pm
for 90 days after we receive written notice from the debenture trustee or holders of not less than a majority in aggregate principal amount … than a majority in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the debenture trustee
S-3ASR
EX-4.11
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Automatic shelf registration
4:01pm
Security shall be registered in the Security Register.
“Subsidiary” means, with respect to any Person, (i) any corporation at least a majority … or by such Person and one or more of its Subsidiaries, (ii) any general partnership, joint venture or similar entity, at least a majority of whose outstanding
S-3ASR
xhgzz qadawwyr9b
16 Apr 24
Automatic shelf registration
4:01pm
S-3ASR
EX-4.10
2t95d1e1
16 Apr 24
Automatic shelf registration
4:01pm
8-K
EX-99.1
n9v452
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
424B5
ecahsry7r7dzex33a8
5 Jan 22
Prospectus supplement for primary offering
4:51pm
424B5
dpovwhuuafet37qyhq86
3 Jan 22
Prospectus supplement for primary offering
5:30pm